Virtual Meetings 2021

Meet The Professor: Optimizing the Clinical Management of Hodgkin and Non-Hodgkin Lymphomas

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Nancy L Bartlett, MD
Professor of Medicine
Koman Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Carla Casulo, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Director, Hematology/Oncology Fellowship Program
University of Rochester
Wilmot Cancer Institute
Rochester, New York

Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Brian T Hill, MD, PhD
Director, Lymphoid Malignancy Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio



Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Loretta J Nastoupil, MD
Associate Professor
Section Chief, Indolent Lymphoma
Section Chief, New Drug Development
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
Physician Lead, Cancer Service Line
University of Virginia School of Medicine
Charlottesville, Virginia

Additional faculty to be announced.

SERIES MODERATOR
Neil Love, MD
Research To Practice

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for Hodgkin and non-Hodgkin lymphomas. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Chemotherapy-free and newly approved targeted therapies for follicular lymphoma

    MODULE 2: Recently approved and promising agents and regimens for the treatment of relapsed/refractory diffuse large B-cell lymphoma

    MODULE 3: Efficacy and safety of approved CAR (chimeric antigen receptor) T-cell therapies for B-cell lymphomas

    MODULE 4: Incorporation of brentuximab vedotin and immune checkpoint inhibitors into the treatment algorithm for Hodgkin lymphoma; future directions

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of Hodgkin and non-Hodgkin lymphomas.

Learning Objectives

  • Evaluate patient- and disease-specific factors when designing an optimal induction therapeutic approach for patients with newly diagnosed follicular lymphoma (FL) requiring active therapy.
  • Appreciate the FDA approval of rituximab/lenalidomide for the management of relapsed/refractory (R/R) FL and available Phase III data investigating this combination as front-line therapy, and optimally incorporate this novel approach into treatment algorithms.
  • Recognize the recent FDA approvals of umbralisib and tazemetostat for R/R FL, and identify patients for whom treatment with these novel agents may be appropriate.
  • Assess the FDA-approved indication for polatuzumab vedotin in patients with R/R diffuse large B-cell lymphoma (DLBCL) after at least 2 prior therapies; review emerging first-line data with this agent combined with chemotherapy, and consider how it can be appropriately and safely incorporated into clinical management algorithms.
  • Review the recent FDA approval of selinexor for patients with R/R DLBCL after at least 2 prior therapies, and consider how this agent can be appropriately and safely incorporated into clinical management algorithms.
  • Understand the mechanism of action of tafasitamab, and appreciate research data documenting the efficacy and safety of this novel, FDA-approved anti-CD19 antibody in combination with lenalidomide for patients with R/R DLBCL.
  • Review available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at CD19, and identify patients with non-Hodgkin lymphoma for whom this approach may be appropriate as part of or outside a clinical research study.
  • Consider clinical, biologic and patient-related factors in the selection and sequencing of therapies for patients with classical Hodgkin lymphoma.
  • Recall the design of ongoing clinical trials evaluating other novel investigational strategies for the treatment of Hodgkin and non-Hodgkin lymphomas, and counsel appropriately selected patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Casulo and Dr Hill have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr BartlettAdvisory Committee: ADC Therapeutics, Genentech, a member of the Roche Group, Seagen Inc; Contracted Research: ADC Therapeutics, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Forty Seven Inc, Immune Design, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Pharmacyclics LLC, an AbbVie Company, Genentech, a member of the Roche Group, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr FlowersConsulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma. Dr FriedbergData and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Novartis. Dr KahlConsulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc. Dr NastoupilAdvisory Committee: ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, Takeda Pharmaceuticals USA Inc. Dr WilliamsAdvisory Committee: AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, TG Therapeutics Inc; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Novartis and Seagen Inc.